共查询到20条相似文献,搜索用时 31 毫秒
1.
Byrns MC Jin Y Penning TM 《The Journal of steroid biochemistry and molecular biology》2011,125(1-2):95-104
There is considerable interest in the development of an inhibitor of aldo-keto reductase (AKR) 1C3 (type 5 17β-hydroxysteroid dehydrogenase and prostaglandin F synthase) as a potential therapeutic for both hormone-dependent and hormone-independent cancers. AKR1C3 catalyzes the reduction of 4-androstene-3,17-dione to testosterone and estrone to 17β-estradiol in target tissues, which will promote the proliferation of hormone dependent prostate and breast cancers, respectively. AKR1C3 also catalyzes the reduction of prostaglandin (PG) H(2) to PGF(2α) and PGD(2) to 9α,11β-PGF(2), which will limit the formation of anti-proliferative prostaglandins, including 15-deoxy-Δ(12,14)-PGJ(2), and contribute to proliferative signaling. AKR1C3 is overexpressed in a wide variety of cancers, including breast and prostate cancer. An inhibitor of AKR1C3 should not inhibit the closely related isoforms AKR1C1 and AKR1C2, as they are involved in other key steroid hormone biotransformations in target tissues. Several structural leads have been explored as inhibitors of AKR1C3, including non-steroidal anti-inflammatory drugs, steroid hormone analogues, flavonoids, cyclopentanes, and benzodiazepines. Inspection of the available crystal structures of AKR1C3 with multiple ligands bound, along with the crystal structures of the other AKR1C isoforms, provides a structural basis for the rational design of isoform specific inhibitors of AKR1C3. We find that there are subpockets involved in ligand binding that are considerably different in AKR1C3 relative to the closely related AKR1C1 or AKR1C2 isoforms. These pockets can be used to further improve the binding affinity and selectivity of the currently available AKR1C3 inhibitors. Article from the special issue on Targeted Inhibitors. 相似文献
2.
Human steroid 5β-reductase (aldo-keto reductase 1D1) catalyzes the stereospecific NADPH-dependent reduction of the C4-C5 double bond of Δ4-ketosteroids to yield an A/B cis-ring junction. This cis-configuration is crucial for bile acid biosynthesis and plays important roles in steroid metabolism. The biochemical properties of the enzyme have not been thoroughly studied and conflicting data have been reported, partially due to the lack of highly homogeneous protein. In the present study, we systematically determined the substrate specificity of homogeneous human recombinant AKR1D1 using C18, C19, C21, and C27 Δ4-ketosteroids and assessed the pH-rate dependence of the enzyme. Our results show that AKR1D1 proficiently reduced all the steroids tested at physiological pH, indicating AKR1D1 is the only enzyme necessary for all the 5β-steroid metabolites present in humans. Substrate inhibition was observed with C18 to C21 steroids provided that the C11 position was unsubstituted. This structure activity relationship can be explained by the existence of a small alternative substrate binding pocket revealed by the AKR1D1 crystal structure. Non-steroidal anti-inflammatory drugs which are potent inhibitors of the related AKR1C enzymes do not inhibit AKR1D1. By contrast chenodeoxycholate and ursodeoxycholate were found to be potent non-competitive inhibitors suggesting that bile-acids may regulate their own synthesis at the level of AKR1D1 inhibition. 相似文献
3.
El-Kabbani O Dhagat U Hara A 《The Journal of steroid biochemistry and molecular biology》2011,125(1-2):105-111
Human 20α-hydroxysteroid dehydrogenase (AKR1C1), a member of the aldo-keto reductase (AKR) superfamily, is one of four isoforms (with >84% amino acid sequence identity) existing in human tissues. AKR1C1 most efficiently reduces biologically active progesterone and 5α-pregnan-3α-ol-20-one into their corresponding 20α-hydroxysteroids among the isoforms. The enzyme also accepts endogenous and xenobiotic non-steroidal carbonyl compounds as the substrates. In addition to the up-regulation of the AKR1C1 gene in cancer cells, the enzyme's over-expression in the cells of lung, ovary, uterine cervix, skin and colon carcinomas was reported to be associated with resistance against several anticancer agents. Thus, AKR1C1 may be a marker of the above cancers and a target of poor prognosis in cancer therapy. The recently determined X-ray crystal structures of AKR1C1/NADP(+)/20α-hydroxyprogesterone and AKR1C1/NADP(+)/3,5-dichlorosalicylic acid ternary complexes have provided a strong foundation for structure-based design methods to improve inhibitor selectivity and potency. In this review we provide an overview of the different types of AKR1C1 inhibitors and an update on the design of potent and selective inhibitors based on the crystal structure of the enzyme-inhibitor complex. Article from the Special issue on Targeted Inhibitors. 相似文献
4.
The stereospecific 5β-reduction of Δ(4)-3-ketosterols is very difficult to achieve chemically and introduces a 90° bend between ring A and B of the planar steroid. In mammals, the reaction is catalyzed by steroid 5β-reductase, a member of the aldo-keto reductase (AKR) family. The human enzyme, AKR1D1, plays an essential role in bile-acid biosynthesis since the 5β-configuration is required for the emulsifying properties of bile. Deficient 5β-reductase activity can lead to cholestasis and neo-natal liver failure and is often lethal if it remains untreated. In five patients with 5β-reductase deficiency, sequencing revealed individual, non-synonymous point mutations in the AKR1D1 gene: L106F, P133R, G223E, P198L and R261C. However, mapping these mutations to the AKR1D1 crystal structure failed to reveal any obvious involvement in substrate or cofactor binding or catalytic mechanism, and it remained unclear whether these mutations could be causal for the observed disease. We analyzed the positions of the reported mutations and found that they reside in highly conserved portions of AKR1D1 and hypothesized that they would likely lead to changes in protein folding, and hence enzyme activity. Attempts to purify the mutant enzymes for further characterization by over-expression in Escherichia coli yielded sufficient amounts of only one mutant (P133R). This enzyme exhibited reduced K(m) and k(cat) values with the bile acid intermediate Δ(4)-cholesten-7α-ol-3-one as substrate reminiscent of uncompetitive inhibition. In addition, P133R displayed no change in cofactor affinity but was more thermolabile as judged by CD-spectroscopy. When all AKR1D1 mutants were expressed in HEK 293 cells, protein expression levels and enzyme activity were dramatically reduced. Furthermore, cycloheximide treatment revealed decreased stability of several of the mutants compared to wild type. Our data show, that all five mutations identified in patients with functional bile acid deficiency strongly affected AKR1D1 enzyme functionality and therefore may be causal for this disease. 相似文献
5.
Jason E. Drury Luigi Di Costanzo Trevor M. Penning David W. Christianson 《The Journal of biological chemistry》2009,284(30):19786-19790
The Δ4-3-ketosteroid functionality is present in nearly all steroid hormones apart from estrogens. The first step in functionalization of the A-ring is mediated in humans by steroid 5α- or 5β-reductase. Finasteride is a mechanism-based inactivator of 5α-reductase type 2 with subnanomolar affinity and is widely used as a therapeutic for the treatment of benign prostatic hyperplasia. It is also used for androgen deprivation in hormone-de pend ent prostate carcinoma, and it has been examined as a chemopreventive agent in prostate cancer. The effect of finasteride on steroid 5β-reductase (AKR1D1) has not been previously reported. We show that finasteride competitively inhibits AKR1D1 with low micromolar affinity but does not act as a mechanism-based inactivator. The structure of the AKR1D1·NADP+·finasteride complex determined at 1.7 Å resolution shows that it is not possible for NADPH to reduce the Δ1-2-ene of finasteride because the cofactor and steroid are not proximal to each other. The C3-ketone of finasteride accepts hydrogen bonds from the catalytic residues Tyr-58 and Glu-120 in the active site of AKR1D1, providing an explanation for the competitive inhibition observed. This is the first reported structure of finasteride bound to an enzyme involved in steroid hormone metabolism.The Δ4-3-ketosteroid functionality is present in many important steroid hormones, e.g. testosterone, cortisone, and progesterone. An initial step in steroid hormone metabolism is the reduction of the Δ4-ene, which in humans is mediated by steroid 5α-reductases (SRD5A1, SRD5A2) or steroid 5β-reductase (AKR1D1)3 to yield the corresponding 5α- or 5β-dihydrosteroids, respectively (1, 2). The products of these reactions are not always inactive. 5α-Reductase is responsible for the conversion of testosterone to 5α-dihydrotestosterone (5α-DHT), which is the most potent natural ligand for the androgen receptor. By contrast, in addition to being involved in bile acid biosynthesis, 5β-reductase is responsible for generating 5β-pregnanes, which are natural ligands for the pregnane-X receptor (PXR) in the liver (3, 4). PXR is involved in the induction of CYP3A4, which is responsible for the metabolism of a large proportion of drugs (5, 6). Thus both 5α-reductase and 5β-reductase are involved in the formation of potent ligands for nuclear receptors.Finasteride is a selective 5α-reductase type 2 inhibitor that reduces plasma 5α-dihydrotestosterone levels and shrinks the size of the prostate (7). It is a widely used therapeutic agent in the treatment of benign prostatic hyperplasia (8, 9), it is used in androgen deprivation therapy to treat prostate cancer (10), and it has been examined as a chemopreventive agent for hormone-dependent prostate cancer (11). Finasteride was originally thought to act as a competitive inhibitor with nanomolar affinity for 5α-reductase type 2 (12). More recently, it was found that finasteride acts as a mechanism-based inactivator of this enzyme (13). Subsequent to inhibitor binding, there is hydride transfer from the NADPH cofactor to the Δ1-2-ene double bond of finasteride. The intermediate enolate tautomerizes at the enzyme active site to form a bisubstrate analogue in which dihydrofinasteride is covalently bound to NADP+ (13). The bisubstrate analogue has subnanomolar affinity for 5α-reductase type 2 (Fig. 1). No structural information exists for 5α-reductase type 1 or type 2; therefore, it is not possible to determine how finasteride would bind to the active site of a human steroid double bond reductase in the absence of an experimentally determined crystal structure.Open in a separate windowFIGURE 1.Mechanism-based inactivation of 5α-reductase type 2 by finasteride. Adapted from Bull et al. (13). R = −C(=O)-NH2; PADPR = 2′-phosphoadenosine-5″-diphosphoribose.Human steroid 5β-reductase is a member of the aldo-keto reductase (AKR) superfamily and is formally designated (AKR1D1) (14). The AKRs are soluble NADP(H)-dependent oxidoreductases with monomeric molecular masses of 37 kDa. These enzymes are amenable to x-ray crystallography, and during the last year, we and others have reported crystal structures of ternary complexes of AKR1D1 (15–17). The ternary complexes containing steroid substrates include: AKR1D1·NADP+·testosterone (PDB: 3BUR), AKR1D1·NADP+·progesterone (PDB: 3COT), AKR1D1·NADP+·cortisone (PDB: 3CMF), and AKR1D1·NADP+·Δ4-androstene-3,17-dione (PDB: 3CAS) (17). In addition, ternary complexes containing the products 5β-dihydroprogesterone (PDB: 3CAV) and 5β-dihydrotestosterone (PDB: 3DOP) have also been described (16, 18).As part of an ongoing inhibitor screen of AKR1D1, we now report that finasteride acts as a competitive inhibitor with low micromolar affinity. Additionally, we report the x-ray crystal structure of the AKR1D1·NADP+·finasteride complex. 相似文献
6.
α-Synuclein is a conserved protein that is a key component in neurodegenerative plaques [1,2]. α-Synuclein binds strongly to phospholipase Cβ (PLCβ) and promotes Ca2+ release in cells. Here, we show that expression of α-synuclein increases the cellular level of PLCβ1 in two neuronal cell lines: PC12 and SK-N-S-SH. The increase in PLCβ1 is not accompanied by changes in the level of RNA or in ubiquitination. Instead, we find that α-synuclein protects PLCβ1 from trypsin digestion and from degradation by the Ca(+2) activated protease calpain. Calpain removes the C-terminal region of the enzyme which mediates activation by Gα(q). We find that in SK-N-SH cells, α-synuclein reduced degradation of PLCβ1 by calpain during Ca2+ signaling allowing the enzyme to remain sensitive to Gα(q) activation. Taken together, our studies show that α-synuclein protects the integrity of PLCβ1 and its ability to be activated by Gα(q), which may in turn impact Ca2+ signaling. 相似文献
7.
Adeniji AO Twenter BM Byrns MC Jin Y Winkler JD Penning TM 《Bioorganic & medicinal chemistry letters》2011,21(5):1464-1468
Aldo-keto reductase 1C3 (AKR1C3) also known as type 5 17β-hydroxysteroid dehydrogenase has been implicated as one of the key enzymes driving the elevated intratumoral androgen levels observed in castrate resistant prostate cancer (CRPC). AKR1C3 inhibition therefore presents a rational approach to managing CRPC. Inhibitors should be selective for AKR1C3 over other AKR1C enzymes involved in androgen metabolism. We have synthesized 2-, 3-, and 4-(phenylamino)benzoic acids and identified 3-(phenylamino)benzoic acids that have nanomolar affinity and exhibit over 200-fold selectivity for AKR1C3 versus other AKR1C isoforms. The AKR1C3 inhibitory potency of the 4′-substituted 3-(phenylamino)benzoic acids shows a linear correlation with both electronic effects of substituents and the pKa of the carboxylic acid and secondary amine groups, which are interdependent. These compounds may be useful in treatment and/or prevention of CRPC as well as understanding the role of AKR1C3 in endocrinology. 相似文献
8.
Byrns MC Mindnich R Duan L Penning TM 《The Journal of steroid biochemistry and molecular biology》2012,130(1-2):7-15
Type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) is the major enzyme in the prostate that reduces 4-androstene-3,17-dione (Δ(4)-Adione) to the androgen receptor (AR) ligand testosterone. AKR1C3 is upregulated in prostate cancer (PCa) and castrate resistant prostate cancer (CRPC) that develops after androgen deprivation therapy. PCa and CRPC often depend on intratumoral androgen biosynthesis and upregulation of AKR1C3 could contribute to intracellular synthesis of AR ligands and stimulation of proliferation through AR signaling. To test this hypothesis, we developed an LNCaP prostate cancer cell line overexpressing AKR1C3 (LNCaP-AKR1C3) and compared its metabolic and proliferative responses to Δ(4)-Adione treatment with that of the parental, AKR1C3 negative LNCaP cells. In LNCaP and LNCaP-AKR1C3 cells, metabolism proceeded via 5α-reduction to form 5α-androstane-3,17-dione and then (epi)androsterone-3-glucuronide. LNCaP-AKR1C3 cells made significantly higher amounts of testosterone-17β-glucuronide. When 5α-reductase was inhibited by finasteride, the production of testosterone-17β-glucuronide was further elevated in LNCaP-AKR1C3 cells. When AKR1C3 activity was inhibited with indomethacin the production of testosterone-17β-glucuronide was significantly decreased. Δ(4)-Adione treatment stimulated cell proliferation in both cell lines. Finasteride inhibited LNCaP cell proliferation, consistent with 5α-androstane-3,17-dione acting as the major metabolite that stimulates growth by binding to the mutated AR. However, LNCaP-AKR1C3 cells were resistant to the growth inhibitory properties of finasteride, consistent with the diversion of Δ(4)-Adione metabolism from 5α-reduced androgens to increased formation of testosterone. Indomethacin did not result in differences in Δ(4)-Adione induced proliferation since this treatment led to the same metabolic profile in LNCaP and LNCaP-AKR1C3 cells. We conclude that AKR1C3 overexpression diverts androgen metabolism to testosterone that results in proliferation in androgen sensitive prostate cancer. This effect is seen despite high levels of uridine glucuronosyl transferases suggesting that AKR1C3 activity can surmount the effects of this elimination pathway. Treatment options in prostate cancer that target 5α-reductase where AKR1C3 co-exists may be less effective due to the diversion of Δ(4)-Adione to testosterone. 相似文献
9.
10.
Chen M Drury JE Christianson DW Penning TM 《The Journal of biological chemistry》2012,287(20):16609-16622
Human aldo-keto reductase 1D1 (AKR1D1) and AKR1C enzymes are essential for bile acid biosynthesis and steroid hormone metabolism. AKR1D1 catalyzes the 5β-reduction of Δ(4)-3-ketosteroids, whereas AKR1C enzymes are hydroxysteroid dehydrogenases (HSDs). These enzymes share high sequence identity and catalyze 4-pro-(R)-hydride transfer from NADPH to an electrophilic carbon but differ in that one residue in the conserved AKR catalytic tetrad, His(120) (AKR1D1 numbering), is substituted by a glutamate in AKR1D1. We find that the AKR1D1 E120H mutant abolishes 5β-reductase activity and introduces HSD activity. However, the E120H mutant unexpectedly favors dihydrosteroids with the 5α-configuration and, unlike most of the AKR1C enzymes, shows a dominant stereochemical preference to act as a 3β-HSD as opposed to a 3α-HSD. The catalytic efficiency achieved for 3β-HSD activity is higher than that observed for any AKR to date. High resolution crystal structures of the E120H mutant in complex with epiandrosterone, 5β-dihydrotestosterone, and Δ(4)-androstene-3,17-dione elucidated the structural basis for this functional change. The glutamate-histidine substitution prevents a 3-ketosteroid from penetrating the active site so that hydride transfer is directed toward the C3 carbonyl group rather than the Δ(4)-double bond and confers 3β-HSD activity on the 5β-reductase. Structures indicate that stereospecificity of HSD activity is achieved because the steroid flips over to present its α-face to the A-face of NADPH. This is in contrast to the AKR1C enzymes, which can invert stereochemistry when the steroid swings across the binding pocket. These studies show how a single point mutation in AKR1D1 can introduce HSD activity with unexpected configurational and stereochemical preference. 相似文献
11.
El-Kabbani O Dhagat U Soda M Endo S Matsunaga T Hara A 《Bioorganic & medicinal chemistry letters》2011,21(8):2564-2567
Human 20α-hydroxysteroid dehydrogenase (AKR1C1) is an important drug target due to its role in the development of lung and endometrial cancers, premature birth and neuronal disorders. We report the crystal structure of AKR1C1 complexed with the first structure-based designed inhibitor 3-chloro-5-phenylsalicylic acid (Ki = 0.86 nM) bound in the active site. The binding of 3-chloro-5-phenylsalicylic acid to AKR1C1 resulted in a conformational change in the side chain of Phe311 to accommodate the bulky phenyl ring substituent at the 5-position of the inhibitor. The contributions of the nonconserved residues Leu54, Leu306, Leu308 and Phe311 to the binding were further investigated by site-directed mutagenesis, and the effects of the mutations on the Ki value were determined. The Leu54Val and Leu306Ala mutations resulted in 6- and 81-fold increases, respectively, in Ki values compared to the wild-type enzyme, while the remaining mutations had little or no effects. 相似文献
12.
13.
14.
Integrin α5β1 is a major cellular receptor for the extracellular matrix protein fibronectin and plays a fundamental role during mammalian development. A crystal structure of the α5β1 integrin headpiece fragment bound by an allosteric inhibitory antibody was determined at a 2.9-Å resolution both in the absence and presence of a ligand peptide containing the Arg-Gly-Asp (RGD) sequence. The antibody-bound β1 chain accommodated the RGD ligand with very limited structural changes, which may represent the initial step of cell adhesion mediated by nonactivated integrins. Furthermore, a molecular dynamics simulation pointed to an important role for Ca2+ in the conformational coupling between the ligand-binding site and the rest of the molecule. The RGD-binding pocket is situated at the center of a trenchlike exposed surface on the top face of α5β1 devoid of glycosylation sites. The structure also enabled the precise prediction of the acceptor residue for the auxiliary synergy site of fibronectin on the α5 subunit, which was experimentally confirmed by mutagenesis and kinetic binding assays. 相似文献
15.
16.
《Structure (London, England : 1993)》2019,27(9):1443-1451.e6
- Download : Download high-res image (138KB)
- Download : Download full-size image
17.
Chao JT Gui P Zamponi GW Davis GE Davis MJ 《American journal of physiology. Cell physiology》2011,300(3):C477-C489
Engagement of α(5)β(1)-integrin by fibronectin (FN) acutely enhances Cav1.2 channel (Ca(L)) current in rat arteriolar smooth muscle and human embryonic kidney cells (HEK293-T) expressing Ca(L). Using coimmunoprecipitation strategies, we show that coassociation of Ca(L) with α(5)- or β(1)-integrin in HEK293-T cells is specific and depends on cell adhesion to FN. In rat arteriolar smooth muscle, coassociations between Ca(L) and α(5)β(1)-integrin and between Ca(L) and phosphorylated c-Src are also revealed and enhanced by FN treatment. Using site-directed mutagenesis of Ca(L) heterologously expressed in HEK293-T cells, we identified two regions of Ca(L) required for these interactions: 1) COOH-terminal residues Ser(1901) and Tyr(2122), known to be phosphorylated by protein kinase A (PKA) and c-Src, respectively; and 2) two proline-rich domains (PRDs) near the middle of the COOH terminus. Immunofluorescence confocal imaging revealed a moderate degree of wild-type Ca(L) colocalization with β(1)-integrin on the plasma membrane. Collectively, our results strongly suggest that 1) upon ligation by FN, Ca(L) associates with α(5)β(1)-integrin in a macromolecular complex including PKA, c-Src, and potentially other protein kinases; 2) phosphorylation of Ca(L) at Y(2122) and/or S(1901) is required for association of Ca(L) with α(5)β(1)-integrin; and 3) c-Src, via binding to PRDs that reside in the II-III linker region and/or the COOH terminus of Ca(L), mediates current potentiation following α(5)β(1)-integrin engagement. These findings provide new evidence for how interactions between α(5)β(1)-integrin and FN can modulate Ca(L) entry and consequently alter the physiological function of multiple types of excitable cells. 相似文献
18.
Yongmei Pu Susan H. Garfield Noemi Kedei Peter M. Blumberg 《The Journal of biological chemistry》2009,284(2):1302-1312
Classic and novel protein kinase C (PKC) isozymes contain two zinc finger
motifs, designated “C1a” and “C1b” domains, which
constitute the recognition modules for the second messenger diacylglycerol
(DAG) or the phorbol esters. However, the individual contributions of these
tandem C1 domains to PKC function and, reciprocally, the influence of protein
context on their function remain uncertain. In the present study, we prepared
PKCδ constructs in which the individual C1a and C1b domains were
deleted, swapped, or substituted for one another to explore these issues. As
isolated fragments, both the δC1a and δC1b domains potently bound
phorbol esters, but the binding of [3H]phorbol 12,13-dibutyrate
([3H]PDBu) by the δC1a domain depended much more on the
presence of phosphatidylserine than did that of the δC1b domain. In
intact PKCδ, the δC1b domain played the dominant role in
[3H]PDBu binding, membrane translocation, and down-regulation. A
contribution from the δC1a domain was nonetheless evident, as shown by
retention of [3H]PDBu binding at reduced affinity, by increased
[3H]PDBu affinity upon expression of a second δC1a domain
substituting for the δC1b domain, and by loss of persistent plasma
membrane translocation for PKCδ expressing only the δC1b domain,
but its contribution was less than predicted from the activity of the isolated
domain. Switching the position of the δC1b domain to the normal position
of the δC1a domain (or vice versa) had no apparent effect on the
response to phorbol esters, suggesting that the specific position of the C1
domain within PKCδ was not the primary determinant of its activity.One of the essential steps for protein kinase C
(PKC)2 activation is
its translocation from the cytosol to the membranes. For conventional
(α, βI, βII, and γ) and novel (δ, ε, η,
and θ) PKCs, this translocation is driven by interaction with the
lipophilic second messenger sn-1,2-diacylglycerol (DAG), generated
from phosphatidylinositol 4,5-bisphosphate upon the activation of
receptor-coupled phospholipase C or indirectly from phosphatidylcholine via
phospholipase D (1). A pair of
zinc finger structures in the regulatory domain of the PKCs, the
“C1” domains, are responsible for the recognition of the DAG
signal. The DAG-C1 domain-membrane interaction is coupled to a conformational
change in PKC, both causing the release of the pseudosubstrate domain from the
catalytic site to activate the enzyme and triggering the translocation to the
membrane (2). By regulating
access to substrates, PKC translocation complements the intrinsic enzymatic
specificity of PKC to determine its substrate profile.The C1 domain is a highly conserved cysteine-rich motif (∼50 amino
acids), which was first identified in PKC as the interaction site for DAG or
phorbol esters (3). It
possesses a globular structure with a hydrophilic binding cleft at one end
surrounded by hydrophobic residues. Binding of DAG or phorbol esters to the C1
domain caps the hydrophilic cleft and forms a continuous hydrophobic surface
favoring the interaction or penetration of the C1 domain into the membrane
(4). In addition to the novel
and classic PKCs, six other families of proteins have also been identified,
some of whose members possess DAG/phorbol ester-responsive C1 domains. These
are the protein kinase D (5),
the chimaerin (6), the munc-13
(7), the RasGRP (guanyl
nucleotide exchange factors for Ras and Rap1)
(8), the DAG kinase
(9), and the recently
characterized MRCK (myotonic dystrophy kinase-related
Cdc42-binding kinase) families
(10). Of these C1
domain-containing proteins, the PKCs have been studied most extensively and
are important therapeutic targets
(11). Among the drug
candidates in clinical trials that target PKC, a number such as bryostatin 1
and PEP005 are directed at the C1 domains of PKC rather than at its catalytic
site.Both the classic and novel PKCs contain in their N-terminal regulatory
region tandem C1 domains, C1a and C1b, which bind DAG/phorbol ester
(12). Multiple studies have
sought to define the respective roles of these two C1 domains in PKC
regulation, but the issue remains unclear. Initial in vitro binding
measurements with conventional PKCs suggested that 1 mol of phorbol ester
bound per mole of PKC
(13-15).
On the other hand, Stubbs et al., using a fluorescent phorbol ester
analog, reported that PKCα bound two ligands per PKC
(16). Further, site-directed
mutagenesis of the C1a and C1b domains of intact PKCα indicated that the
C1a and C1b domains played equivalent roles for membrane translocation in
response to phorbol 12-myristate 13-acetate (PMA) and (-)octylindolactam V
(17). Likewise, deletion
studies indicated that the C1a and C1b domains of PKCγ bound PDBu
equally with high potency (3,
18). Using a functional assay
with PKCα expression in yeast, Shieh et al.
(19) deleted individual C1
domains and reported that C1a and C1b were both functional and equivalent upon
stimulation by PMA, with either deletion causing a similar reduction in
potency of response, whereas for mezerein the response depended essentially on
the C1a domain, with much weaker response if only the C1b domain was present.
Using isolated C1 domains, Irie et al.
(20) suggested that the C1a
domain of PKCα but not those of PKCβ or PKCγ bound
[3H]PDBu preferentially; different ligands showed a generally
similar pattern but with different extents of selectivity. Using synthesized
dimeric bisphorbols, Newton''s group reported
(21) that, although both C1
domains of PKCβII are oriented for potential membrane interaction, only
one C1 domain bound ligand in a physiological context.In the case of novel PKCs, many studies have been performed on PKCδ
to study the equivalency of the twin C1 domains. The P11G point mutation of
the C1a domain, which caused a 300-fold loss of binding potency in the
isolated domain (22), had
little effect on the phorbol ester-dependent translocation of PKCδ in
NIH3T3 cells, whereas the same mutation of the C1b caused a 20-fold shift in
phorbol ester potency for inducing translocation, suggesting a major role of
the C1b domain for phorbol ester binding
(23). A secondary role for the
C1a domain was suggested, however, because mutation in the C1a domain as well
as the C1b domain caused a further 7-fold shift in potency. Using the same
mutations in the C1a and C1b domains, Bögi et al.
(24) found that the binding
selectivity for the C1a and C1b domains of PKCδ appeared to be
ligand-dependent. Whereas PMA and the indole alkaloids indolactam and
octylindolactam were selectively dependent on the C1b domain, selectivity was
not observed for mezerein, the 12-deoxyphorbol 13-monoesters prostratin and
12-deoxyphorbol 13-phenylacetate, and the macrocyclic lactone bryostatin 1
(24). In in vitro
studies using isolated C1a and C1b domains of PKCδ, Cho''s group
(25) described that the two C1
domains had opposite affinities for DAG and phorbol ester; i.e. the
C1a domain showed high affinity for DAG and the C1b domain showed high
affinity for phorbol ester. No such difference in selectivity was observed by
Irie et al. (20).PKC has emerged as a promising therapeutic target both for cancer and for
other conditions, such as diabetic retinopathy or macular degeneration
(26-30).
Kinase inhibitors represent one promising approach for targeting PKC, and
enzastaurin, an inhibitor with moderate selectivity for PKCβ relative to
other PKC isoforms (but still with activity on some other non-PKC kinases) is
currently in multiple clinical trials. An alternative strategy for drug
development has been to target the regulatory C1 domains of PKC. Strong proof
of principle for this approach is provided by multiple natural products,
e.g. bryostatin 1 and PEP005, which are likewise in clinical trials
and which are directed at the C1 domains. A potential advantage of this
approach is the lesser number of homologous targets, <30 DAG-sensitive C1
domains compared with over 500 kinases, as well as further opportunities for
specificity provided by the diversity of lipid environments, which form a
half-site for ligand binding to the C1 domain. Because different PKC isoforms
may induce antagonistic activities, inhibition of one isoform may be
functionally equivalent to activation of an antagonistic isoform
(31).Along with the benzolactams
(20,
32), the DAG lactones have
provided a powerful synthetic platform for manipulating ligand: C1 domain
interactions (31). For
example, the DAG lactone derivative 130C037 displayed marked selectivity among
the recombinant C1a and C1b domains of PKCα and PKCδ as well as
substantial selectivity for RasGRP relative to PKCα
(33). Likewise, we have shown
that a modified DAG lactone (dioxolanones) can afford an additional point of
contact in ligand binding to the C1b domain of PKCδ
(34). Such studies provide
clear examples that ligand-C1 domain interactions can be manipulated to yield
novel patterns of recognition. Further selectivity might be gained with
bivalent compounds, exploiting the spacing and individual characteristics of
the C1a and C1b domains (35).
A better understanding of the differential roles of the two C1 domains in PKC
regulation is critical for the rational development of such compounds. In this
study, by molecularly manipulating the C1a or C1b domains in intact
PKCδ, we find that both the C1a and C1b domains play important roles in
PKCδ regulation. The C1b domain is predominant for ligand binding and
for membrane translocation of the whole PKCδ molecule. The C1a domain of
intact PKCδ plays only a secondary role in ligand binding but stabilizes
the PKCδ molecule at the plasma membrane for downstream signaling. In
addition, we show that the effect of the individual C1 domains of PKCδ
does not critically depend on their position within the regulatory domain. 相似文献
19.
Vargas-Medrano J Castrejon-Tellez V Plenge F Ramirez I Miranda M 《Neurochemistry international》2011,59(8):1123-1132
The extracellular levels of the neurotransmitter glycine in the brain are tightly regulated by the glycine transporter 1 (GlyT1) and the clearance rate for glycine depends on its rate of transport and the levels of cell surface GlyT1. Over the years, it has been shown that PKC tightly regulates the activity of several neurotransmitter transporters. In the present work, by stably expressing three N-terminus GlyT1 isoforms in porcine aortic endothelial cells and assaying for [32P]-orthophosphate metabolic labeling, we demonstrated that the isoforms GlyT1a, GlyT1b, and GlyT1c were constitutively phosphorylated, and that phosphorylation was dramatically enhanced, in a time dependent fashion, after PKC activation by phorbol ester. The phosphorylation was PKC-dependent, since pre-incubation of the cells with bisindolylmaleimide I, a selective PKC inhibitor, abolished the phorbol ester-induced phosphorylation. Blotting with specific anti-phospho-tyrosine antibodies did not yield any signal that could correspond to GlyT1 tyrosine phosphorylation, suggesting that the phosphorylation occurs at serine and/or threonine residues. In addition, a 23-40%-inhibition on Vmax was obtained by incubation with phorbol ester without a significant change on the apparent Km value. Furthermore, pre-incubation of the cells with the selective PKCα/β inhibitor Gö6976 abolished the downregulation effect of phorbol ester on uptake and phosphorylation, whereas the selective PKCβ inhibitors (PKCβ inhibitor or LY333531) prevented the phosphorylation without affecting glycine uptake, defining a specific role of classical PKC on GlyT1 uptake and phosphorylation. Taken together, these data suggest that conventional PKCα/β regulates the uptake of glycine, whereas PKCβ is responsible for GlyT1 phosphorylation. 相似文献
20.
Persistent infection with hepatitis C virus causes serious liver diseases, such as chronic hepatitis, hepatic cirrhosis and hepatocellular carcinoma. The male gender is one of the critical factors in progression of hepatic fibrosis due to chronic HCV infection; thus female hormones may play a role in delaying the progression of hepatic fibrosis. It has also been reported that women are more likely than men to clear HCV in the acute phase of infection. These observations lead the present authors to the question: do female hormones inhibit HCV infection? In this study using HCV J6/JFH1 and Huh‐7.5 cells, the possible inhibitory effect(s) of female hormones such as 17β‐estradiol (the most potent physiological estrogen) and progesterone on HCV RNA replication, HCV protein synthesis and production of HCV infectious particles (virions) were analyzed. It was found that E2, but not P4, significantly inhibited production of the HCV virion without inhibiting HCV RNA replication or HCV protein synthesis. E2–mediated inhibition of HCV virion production was abolished by a nuclear estrogen receptor (ER) antagonist ICI182780. Moreover, treatment with the ERα‐selective agonist 4, 4′, 4″‐ (4‐propyl‐[1H]‐pyrazole‐1, 3, 5‐triyl)trisphenol (PPT), but not with the ERβ‐selective agonist 2, 3‐bis (4‐hydroxyphenyl)‐propionitrile (DPN) or the G protein‐coupled receptor 30 (GPR30)‐selective agonist 1‐(4‐[6‐bromobenzo 1, 3 dioxol‐5‐yl]‐3a, 4, 5, 9b‐tetrahydro‐3H‐cyclopenta [c] quinolin‐8‐yl)‐ethanone (G‐1), significantly inhibited HCV virion production. Taken together, the present results suggest that the most potent physiological estrogen, E2, inhibits the production of HCV infectious particles in an ERα–dependent manner. 相似文献